Drug Approval | January 05, 2025
CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
Subscribe To Our Newsletter & Stay Updated
